VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Influenza virus DNA vaccine encoding HA from Influenza B virus (B/Ibaraki/2/85)
Vaccine Information
  • Vaccine Name: Influenza virus DNA vaccine encoding HA from Influenza B virus (B/Ibaraki/2/85)
  • Target Pathogen: Influenza virus
  • Target Disease: Influenza (flu)
  • Vaccine Ontology ID: VO_0004019
  • Type: DNA vaccine
  • Status: Research
  • Antigen: Influenza B virus (B/Ibaraki/2/85) HA hemagglutinin
  • HA gene engineering:
    • Type: DNA vaccine construction
    • Description: Plasmid pCAGGSP7/HA was constructed by cloning the PCR product of HA from B/B/Ibaraki/2/85 influenza virus strain (B/Ibaraki) into the plasmid expression vector pCAGGSP7 (Chen et al., 2001).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0005000
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: BALB/c mice were immunized twice, 3 weeks apart, by injection of 30 μg of DNA into the quadriceps muscles with a 26-gauge needle under light anesthesia. A pair of electrode needles were inserted 5 mm apart into the muscle to encompass the DNA injection sites, and electrical pulses were delivered using an electric pulse generator (Electro Square Porator T820M; BTX, San Diego, CA). Three pulses of 100 V each, followed by three pulses of the opposite polarity, each pulse lasting for 50 ms, were delivered to each injection site at a rate of one pulse per second (Chen et al., 2001).
  • Challenge Protocol: Three weeks after the second immunization, mice were challenged with the mouse-adapted B virus, B/Ibaraki/2/85 (40×50% lethal dose (LD50), 104.3 50% egg-infecting dose (EID50)), by intranasal administration of 20 μl of the viral suspension. This virus rapidly replicates in the lung, causing death in 6–8 days in unimmunized mice (Chen et al., 2001).
  • Efficacy: Protection against a lethal influenza B virus infection was examined in BALB/c mice immunized with plasmid DNAs encoding hemagglutinin (HA), neuraminidase (NA and NB) and nucleoprotein (NP) from the B/Ibaraki/2/85 virus. Both HA and NA DNAs conferred complete protection against the lethal challenge in all the tested mouse strains (Chen et al., 2001).
References
Chen et al., 2001: Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Sata T, Kurata T, Tamura S. Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine. 2001; 19(11-12); 1446-1455. [PubMed: 11163667].